Emerald Advisers LLC Sells 574 Shares of SAGE Therapeutics Inc (SAGE)

Emerald Advisers LLC decreased its holdings in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 12.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,911 shares of the biopharmaceutical company’s stock after selling 574 shares during the quarter. Emerald Advisers LLC’s holdings in SAGE Therapeutics were worth $375,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the stock. Schroder Investment Management Group lifted its holdings in shares of SAGE Therapeutics by 17.9% during the 3rd quarter. Schroder Investment Management Group now owns 2,801 shares of the biopharmaceutical company’s stock valued at $396,000 after acquiring an additional 426 shares in the last quarter. WINTON GROUP Ltd lifted its holdings in shares of SAGE Therapeutics by 24.6% during the 3rd quarter. WINTON GROUP Ltd now owns 3,491 shares of the biopharmaceutical company’s stock valued at $493,000 after acquiring an additional 689 shares in the last quarter. United Services Automobile Association lifted its holdings in shares of SAGE Therapeutics by 10.0% during the 2nd quarter. United Services Automobile Association now owns 7,850 shares of the biopharmaceutical company’s stock valued at $1,229,000 after acquiring an additional 713 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in shares of SAGE Therapeutics by 1.4% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 55,242 shares of the biopharmaceutical company’s stock valued at $7,803,000 after acquiring an additional 781 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in shares of SAGE Therapeutics by 1.2% during the 3rd quarter. Swiss National Bank now owns 81,100 shares of the biopharmaceutical company’s stock valued at $11,455,000 after acquiring an additional 1,000 shares in the last quarter.

A number of equities analysts have commented on SAGE shares. BidaskClub lowered shares of SAGE Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Canaccord Genuity set a $220.00 price objective on shares of SAGE Therapeutics and gave the stock a “buy” rating in a report on Thursday, November 1st. Leerink Swann started coverage on shares of SAGE Therapeutics in a report on Monday, November 12th. They issued an “underperform” rating and a $80.00 price objective on the stock. Oppenheimer started coverage on shares of SAGE Therapeutics in a report on Wednesday, October 17th. They issued a “buy” rating and a $170.00 price objective on the stock. Finally, Cowen reiterated a “buy” rating and issued a $207.00 price objective on shares of SAGE Therapeutics in a report on Thursday, November 1st. Two equities research analysts have rated the stock with a sell rating and thirteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $200.58.

In other news, Director James M. Frates sold 7,500 shares of the business’s stock in a transaction dated Wednesday, January 23rd. The shares were sold at an average price of $134.81, for a total value of $1,011,075.00. Following the completion of the sale, the director now owns 11,735 shares of the company’s stock, valued at approximately $1,581,995.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.10% of the stock is currently owned by insiders.

SAGE opened at $143.02 on Friday. The stock has a market capitalization of $6.71 billion, a PE ratio of -20.17 and a beta of 2.93. SAGE Therapeutics Inc has a 1-year low of $79.88 and a 1-year high of $193.87.

SAGE Therapeutics (NASDAQ:SAGE) last released its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.41) by ($0.22). During the same period in the prior year, the company earned ($1.97) EPS. On average, equities research analysts forecast that SAGE Therapeutics Inc will post -7.75 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Emerald Advisers LLC Sells 574 Shares of SAGE Therapeutics Inc (SAGE)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2019/02/03/emerald-advisers-llc-sells-574-shares-of-sage-therapeutics-inc-sage.html.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.